Jakarta, October 14th 2022 - PT Kimia Farma Tbk (KAEF) has performed the Extraordinary General Meeting of Shareholders (EGMS). The EGMS that was performed at Kimia Farma Corporate University, East Jakarta officially changed the composition and nomenclature of the Board of Commissioners and the Board of Directors. The EGMS agreed on the honorable dismissal of Abdul Kadir as President Commissioner and Kamelia Faisal as Independent Commissioner.
Kimia Farma’s EGMS also officially appointed Fachmi Idris as President Commissioner and Rendi Witular as Commissioner. Kimia Farma also changed its Board of Directors’ nomenclature from Marketing, Research and Development Director to Portfolio, Product and Service Director currently held by Jasmine Karsono. In addition, the EGMS also appointed Chairani Harahap as Marketing Director.
Therefore, the new Board of Commissioner and Board of Directors of Kimia Farma are as follow:
BOARD OF COMMISSIONERS
President Commissioner : Fachmi Idris
Commissioner : Dwi Ary Purnomo
Commissioner : Wiku Adisasmito
Commissioner : Rendi Witular
Independent Commissioner : Rahmat Hidayat Pulungan
Independent Commissioner : Musthofa Fauzi
BOARD OF DIRECTORS
President Director : David Utama
Finance and Risk Management Director : Lina Sari
Human Resources Director : Dharma Syahputra
Production and Supply Chain Director : Andi Prazos
Portfolio, Product and Service Director : Jasmine Karsono
Marketing Director : Chairani Harahap
The EGMS also approved the company’s capital increase as regulated by the Financial Service Authority (OJK) Regulation (POJK) Number 32/POJK.04/2015 juncto POJK Number 14/POJK.04/2019, where in the first agenda resolution, Kimia Farma received the approval on the plan of Capital Increase with Preemptive Rights (PMHMETD).